Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury

Kara L. Arvin, Byung H. Han, Yansheng Du, Sui Zhen Lin, Steven M. Paul, David M. Holtzman

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

Hypoxic-ischemic brain injury in the perinatal period is a major cause of morbidity and mortality. Presently, there are no proven effective therapies with which to safeguard the human neonatal brain against this type of injury. Minocycline, a semisynthetic tetracycline, has been shown to be neuroprotective in certain adult ischemic injury/stroke and neurodegenerative disease models. However, minocycline's neuroprotective effects have not been assessed after insults to the neonatal brain. We now report that minocycline administered either immediately before or immediately after a hypoxicischemic insult substantially blocks tissue damage in a rodent model of neonatal hypoxic-ischemic brain injury. Minocycline treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death. To our knowledge, this is the first report of a systemic treatment that can be administered after a hypoxic-ischemic insult, which provides robust, nearly complete neuroprotection to the developing brain. Our data suggest that minocycline or a related neuroprotective tetracycline may be a candidate to consider in human clinical trials to protect the developing brain against hypoxic-ischemic-induced damage.

Original languageEnglish
Pages (from-to)54-61
Number of pages8
JournalAnnals of Neurology
Volume52
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Minocycline
Brain Injuries
Wounds and Injuries
Brain
Tetracycline
Calpain
Neuroprotective Agents
Caspase 3
Neurodegenerative Diseases
Rodentia
Cell Death
Stroke
Clinical Trials
Apoptosis
Morbidity
Mortality

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Arvin, K. L., Han, B. H., Du, Y., Lin, S. Z., Paul, S. M., & Holtzman, D. M. (2002). Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Annals of Neurology, 52(1), 54-61. https://doi.org/10.1002/ana.10242

Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. / Arvin, Kara L.; Han, Byung H.; Du, Yansheng; Lin, Sui Zhen; Paul, Steven M.; Holtzman, David M.

In: Annals of Neurology, Vol. 52, No. 1, 2002, p. 54-61.

Research output: Contribution to journalArticle

Arvin, Kara L. ; Han, Byung H. ; Du, Yansheng ; Lin, Sui Zhen ; Paul, Steven M. ; Holtzman, David M. / Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. In: Annals of Neurology. 2002 ; Vol. 52, No. 1. pp. 54-61.
@article{579f7622864a457eb92d8816c4cbc0e7,
title = "Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury",
abstract = "Hypoxic-ischemic brain injury in the perinatal period is a major cause of morbidity and mortality. Presently, there are no proven effective therapies with which to safeguard the human neonatal brain against this type of injury. Minocycline, a semisynthetic tetracycline, has been shown to be neuroprotective in certain adult ischemic injury/stroke and neurodegenerative disease models. However, minocycline's neuroprotective effects have not been assessed after insults to the neonatal brain. We now report that minocycline administered either immediately before or immediately after a hypoxicischemic insult substantially blocks tissue damage in a rodent model of neonatal hypoxic-ischemic brain injury. Minocycline treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death. To our knowledge, this is the first report of a systemic treatment that can be administered after a hypoxic-ischemic insult, which provides robust, nearly complete neuroprotection to the developing brain. Our data suggest that minocycline or a related neuroprotective tetracycline may be a candidate to consider in human clinical trials to protect the developing brain against hypoxic-ischemic-induced damage.",
author = "Arvin, {Kara L.} and Han, {Byung H.} and Yansheng Du and Lin, {Sui Zhen} and Paul, {Steven M.} and Holtzman, {David M.}",
year = "2002",
doi = "10.1002/ana.10242",
language = "English",
volume = "52",
pages = "54--61",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury

AU - Arvin, Kara L.

AU - Han, Byung H.

AU - Du, Yansheng

AU - Lin, Sui Zhen

AU - Paul, Steven M.

AU - Holtzman, David M.

PY - 2002

Y1 - 2002

N2 - Hypoxic-ischemic brain injury in the perinatal period is a major cause of morbidity and mortality. Presently, there are no proven effective therapies with which to safeguard the human neonatal brain against this type of injury. Minocycline, a semisynthetic tetracycline, has been shown to be neuroprotective in certain adult ischemic injury/stroke and neurodegenerative disease models. However, minocycline's neuroprotective effects have not been assessed after insults to the neonatal brain. We now report that minocycline administered either immediately before or immediately after a hypoxicischemic insult substantially blocks tissue damage in a rodent model of neonatal hypoxic-ischemic brain injury. Minocycline treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death. To our knowledge, this is the first report of a systemic treatment that can be administered after a hypoxic-ischemic insult, which provides robust, nearly complete neuroprotection to the developing brain. Our data suggest that minocycline or a related neuroprotective tetracycline may be a candidate to consider in human clinical trials to protect the developing brain against hypoxic-ischemic-induced damage.

AB - Hypoxic-ischemic brain injury in the perinatal period is a major cause of morbidity and mortality. Presently, there are no proven effective therapies with which to safeguard the human neonatal brain against this type of injury. Minocycline, a semisynthetic tetracycline, has been shown to be neuroprotective in certain adult ischemic injury/stroke and neurodegenerative disease models. However, minocycline's neuroprotective effects have not been assessed after insults to the neonatal brain. We now report that minocycline administered either immediately before or immediately after a hypoxicischemic insult substantially blocks tissue damage in a rodent model of neonatal hypoxic-ischemic brain injury. Minocycline treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death. To our knowledge, this is the first report of a systemic treatment that can be administered after a hypoxic-ischemic insult, which provides robust, nearly complete neuroprotection to the developing brain. Our data suggest that minocycline or a related neuroprotective tetracycline may be a candidate to consider in human clinical trials to protect the developing brain against hypoxic-ischemic-induced damage.

UR - http://www.scopus.com/inward/record.url?scp=0036289498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036289498&partnerID=8YFLogxK

U2 - 10.1002/ana.10242

DO - 10.1002/ana.10242

M3 - Article

VL - 52

SP - 54

EP - 61

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -